Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units, Human Pharma and Animal Health.
Boehringer Ingelheim
BingerStrasse 173
Ingelheim 55216
Germany
+49 (0) 6132 77 0
www.boehringer-ingelheim.com/us/
webmaster@boehringer-ingelheim.com
Respimat® Soft Mist Inhaler
The Respimat® is the benchmark Soft Mist Inhaler (SMI) from Boehringer Ingelheim combining groundbreaking performance with simplicity of operation. The propellant - free Respimat® SMI delivers a metered dose of respiratory medication through a unique nozzle system, the uniblock which produces the slow-moving soft mist.
Strategic Partnership with Kenox Pharmaceuticals
Kenox Pharmaceuticals Inc (Kenox), fast-growing company dedicated to developing innovative Orally Inhaled and Nasal Drug Products (OINDPs), announced a strategic partnership with Boehringer Ingelheim International GmbH (Boehringer), a leading global pharmaceutical company, to promote and develop new inhalation drug products using the Respimat® platform to improve patients’ lives worldwide.
Kenox is the emerging CDMO for soft mist inhaler technology for various third-party molecules, including small molecules and biologics. This provides clients with access to both, e. g. the Respimat® device and Kenox' extensive experience in formulation, development, and manufacturing (proof-of concept studies to Clinical Phase II materials).
More Info
